secwatch.observer — SEC 8-K summary
======================================

Issuer:     JOHNSON & JOHNSON (JNJ)
CIK:        0000200406
Form:       8-K
Filed at:   2023-07-20T23:59:59+00:00
Accession:  0000200406-23-000073
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

JNJ Q2 sales up 6.3% to $25.5B; raises FY guidance; Kenvue spin-off via exchange offer
--------------------------------------------------------------------------------

- Q2 2023 sales $25.53B (+6.3%); operational sales growth 7.5% excluding COVID-19 vaccine 8.9%.
- GAAP diluted EPS $1.96 (+8.9%); adjusted diluted EPS $2.80 (+8.1%).
- FY 2023 adjusted operational sales ex-COVID vaccine and adjusted operational EPS guidance midpoints raised.
- Board authorizes Kenvue share split-off via exchange offer as next step in separation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/200406/000020040623000073/0000200406-23-000073-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/200406/000020040623000073/jnj-20230720.htm
  HTML page:      https://secwatch.observer/filing/0000200406-23-000073

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer